Concepedia

Jack O. Egan

JO

16

Publications

1.9K

Citations

15

H-Index

1992

Active since

Affiliations

Altor BioScience (United States)(Current)

Heat Biologics (United States)

University of Minnesota

University of Vermont

Washington University in St. Louis

Jack O. Egan is an author at Altor BioScience (United States) specializing in medicine, immunology, and immunotherapy.

ORCID

Top concepts

Publications per year

1992–2023

16

Publications

16

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

John Wrangle, Vamsidhar Velcheti, Manish R. Patel et al. · The Lancet Oncology · 2018 · 410 citations

, , +8

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Rizwan Romee, Sarah Cooley, Melissa M. Berrien-Elliott et al. · Blood · 2018 · 397 citations · Full text

Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models

Peter R. Rhode, Jack O. Egan, Wenxin Xu et al. · Cancer Immunology Research · 2015 · 220 citations · Full text

, , +19

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors

Kim Margolin, Chihiro Morishima, Vamsidhar Velcheti et al. · Clinical Cancer Research · 2018 · 199 citations · Full text

Novel Human Interleukin-15 Agonists

Xiaoyun Zhu, Warren D. Marcus, Wenxin Xu et al. · The Journal of Immunology · 2009 · 151 citations · Full text

Rows per page

1–5 of 16